CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy

PURPOSE: (131)I therapy is regularly used following surgery as a part of thyroid cancer management. Despite an overall relatively good prognosis, recurrent or metastatic thyroid cancer is not rare. CD133-expressing cells have been shown to mark thyroid cancer stem cells that possess the characterist...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Chien-Chih, Liu, Ren-Shyan, Yang, An-Hang, Liu, Ching-Sheng, Chi, Chin-Wen, Tseng, Ling-Ming, Tsai, Yi-Fan, Ho, Jennifer H., Lee, Chen-Hsen, Lee, Oscar K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510415/
https://www.ncbi.nlm.nih.gov/pubmed/23081821
http://dx.doi.org/10.1007/s00259-012-2242-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510415/
https://www.ncbi.nlm.nih.gov/pubmed/23081821
http://dx.doi.org/10.1007/s00259-012-2242-5

Ejemplares similares